CF PharmTech, Inc. reported the repurchase of 32,000 H-shares on 19 May 2026 via on-market transactions on the Hong Kong Stock Exchange. The shares were bought at prices between HK$20.12 and HK$20.80, with a volume-weighted average cost of HK$20.36, bringing the cash outlay to approximately HK$0.65 million.

Following the transaction, the number of issued shares (excluding treasury shares) fell from 301,436,086 to 301,404,086, a marginal reduction of 0.0106%. Treasury shares increased to 819,500, while the total issued share count remained unchanged at 302,223,586, as the repurchased shares are being held in treasury rather than cancelled.

The buyback forms part of a repurchase mandate approved on 16 December 2025, which authorises the company to buy back up to 30,222,358 shares. Cumulative repurchases under this mandate now stand at 819,500 shares, representing 0.2712% of the issued share capital on the mandate date. In accordance with Hong Kong listing rules, CF PharmTech is subject to a moratorium on issuing new shares or disposing of treasury shares until 18 June 2026.